retatrutide investigational
Selected indexed studies
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. (Eur J Clin Pharmacol, 2024) [PMID:38367045]
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (Diabetes Care, 2024) [PMID:38843460]
- Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies. (Cureus, 2025) [PMID:41393574]
_Worker-drafted node — pending editorial review._
Connections
retatrutide investigational is a side effect of
Sources
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. (2024) pubmed
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (2024) pubmed
- Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies. (2025) pubmed
- Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity. (2024) pubmed
- Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. (2025) pubmed
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. (2026) pubmed
- Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050. (2026) pubmed